Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Second-dose MMR non-inferiority study in children aged 4 to 6 years
2011-004638-32Phase 3
- Sponsor
- GSK
- Start
- Jun 2015
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, Live Biotherapeutic Products → Microbiome Therapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of measles, mumps, and rubella vaccine, varicella virus vaccine live and diphtheria + tetanus + acellular pertussis + inactivated poliovirus vaccine (adsorbed) in measles, mumps, rubella and 1 more (2 arms), sponsored by GSK. Primary endpoints: MMR immunogenicity non-inferiority at Day 42 and Seroresponse rates to measles, mumps, and rubella at Day 42.
02
Drugs
measles, mumps, and rubella vaccinevaricella virus vaccine livediphtheria + tetanus + acellular pertussis + inactivated poliovirus vaccine (adsorbed)
03
Conditions
measlesmumpsrubellachickenpox
Beyond the preview
Go deeper on 2011-004638-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004638-32.